Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT 2022

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Presenter: Davide Cao

September 18, 2022

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Presenter: Matthew J. Price, Shephal Doshi

September 15, 2014

Presentation LAA 2014

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Presenter: David R. Holmes

July 19, 2014

Presentation LAA 2014

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Outcomes Data with the Amplatzer Cardiac Plug in Anticoagulant Eligible and Ineligible Patients

Presenter: Josep Rod?s-Cabau

July 19, 2014

Presentation LAA 2014

Novel Anticoagulants

Presenter: Michael D. Ezekowitz

July 17, 2014

Presentation TCT 2013

Current Use Patterns of Chronic Oral Anticoagulation: Penetration, Agent Selection, Complications, and Defining the Anticoagulant Ineligible Patient

Presenter: Michael Ezekowitz

October 27, 2013

Presentation TCT 2012

The New Anticoagulants: A Meaningful Step Forward?

Presenter: Gregg Stone

October 23, 2012

Advertisement

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient?

Watchman: Randomized Trial Data in Anticoagulant Eligible Patients(from PROTECT AF to CAP to PREVAIL)

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Outcomes Data with the Amplatzer Cardiac Plug in Anticoagulant Eligible and Ineligible Patients

Novel Anticoagulants

Current Use Patterns of Chronic Oral Anticoagulation: Penetration, Agent Selection, Complications, and Defining the Anticoagulant Ineligible Patient

The New Anticoagulants: A Meaningful Step Forward?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content